Breast cancer is the most prevalent cancer in women. It accounted for 29% (232 670) of all new cancers and 15% (40 000) of total cancer deaths in the United States in 2014 ([@bib31]). The death rate for breast cancer is down from its peak rate by 34% as a result of improvements in early detection and treatment ([@bib2]; [@bib11]; [@bib10]). Despite developments in surgery and new chemotherapy regimens over the last few decades, disease progression typically occurs in advanced breast cancers, likely due to the presence or the development of chemoresistant tumours ([@bib26]). Therefore, the ability to predict a response before commencing chemotherapy would be beneficial to patients who are unlikely to respond to the drugs and could save them from unnecessary drug toxicity. Although mechanisms of chemoresistance are multiple, it has long been recognised that hypoxic cells, such as those found in the highly hypoxic core areas of tumours, are the most chemoresistant cells ([@bib18]; [@bib23]). To survive these difficult conditions, lacking O~2~, cells necessarily adopt strategies of resistance, such as enhanced glycolysis or overexpression of anti-apoptotic factors ([@bib32]; [@bib3]).

Among the glycolytic enzymes, phosphoglycerate kinase-1 (PGK1) catalyses a crucial step of glycolysis, transferring a phosphate group from 1,3-biphosphoglycerate to ADP, forming ATP and 3-phosphoglycerate ([@bib34]). PGK1 is regulated by hypoxia-inducible factor-1*α* ([@bib8]). In addition to its function as a glycolytic pathway enzyme, PGK1 is also believed to be involved in tumour biology ([@bib17]), angiogenesis ([@bib19]), DNA replication and repair in mammalian nuclei ([@bib33]; [@bib27]) and cancer metastasis ([@bib40]). Further, PGK1 is involved in the onset of malignancies, such as pancreatic cancer ([@bib16]), liver cancer ([@bib1]) and gastric cancer ([@bib38]; [@bib39]). In patients suffering from breast cancer, PGK1 expression has been reported to be increased ([@bib17]) and to be associated with Her-2 status ([@bib37]). Nevertheless, the molecular mechanisms of the variable PGK1 expression and its clinical significance in terms of survival status remain unclear.

Real-time quantitative PCR (real-time qPCR) and western blotting were used to verify PGK1 expression in fresh cancer tissues and their matched normal tissues. To further elucidate the issues, we established a tissue microarray (TMA) comprising 401 breast cancer tissues and 123 matched normal tissues. Then, the correlation between PGK1 expression and the clinicopathologic features was analysed. This study was performed in accordance with the REMARK criteria ([@bib21]).

Materials and methods
=====================

Patients and clinical samples
-----------------------------

This study used archival material from the Department of Pathology at the Harbin Medical University Cancer Hospital, including tissues from 401 consecutive patients with histologically confirmed breast cancer and 123 matched normal tissue samples, all from 2006. Fresh cancer tissues and their matched normal tissues from 46 patients were collected and stored at −80 °C immediately after resection to extract protein and RNA. The cancer tissues and their matched normal tissues were examined by two pathologists. All of the patients were invasive breast cancer patients. The patients who presented with recurrent tumour, metastatic disease at presentation, bilateral tumours, other previous tumours or those who had previously received neoadjuvant treatment were excluded. All protocols were reviewed and approved by the Ethical Committee of Harbin Medical University in Harbin, China. All patients gave informed consent for the diagnostic procedures and the proposed treatment.

The clinicopathologic characteristics of the 401 breast cancer patients were described in [Table 1](#tbl1){ref-type="table"}. The median age of the patients was 49 years (range, 28--78). Among all of the patients, lymph node metastasis (LNM) was present in 224 patients (55.9%) and absent in 177 patients (44.1%). A total of 267 (66.6%) patients were classified as stage I and II and 134 (33.4%) were stage III. Of 401 patients, 129 received standard paclitexel-based combination chemotherapy after surgery consisting of six courses of treatment.

All breast cancer patients were tested for ER, PR, Her-2, P53 and Ki67, assayed in paraffin-embedded, formation-fixed tissue using antibodies against the proteins ER, PR, Her-2, P53 and Ki67 (Zhong shan-Bio Co., Beijing, China). Immunohistochemical (IHC) staining for ER and PR was performed using a conventional detection method and was considered positive if 1% or more of the nuclei in the invasive component of the tumour were stained ([@bib14]). Positive staining for Her-2 was defined based on the percentage of tumour cells and the intensity of membrane staining. No staining observed or membrane staining of fewer than 10% of the tumour cells was scored as 0. Faint or barely perceptible incomplete membrane staining detected in more than 10% of the tumour cells was scored as 1+. Weak to moderately complete membrane staining observed in more than 10% of the tumour cells was scored as 2+. Strong complete membrane staining observed in more than 10% of the tumour cells was scored as 3+. Scores of 0 to 1+ were regarded as negative and 3+ were regarded as positive ([@bib15]). We selected a Ki67 index of 14% as the optimal cut point for human visual assessment ([@bib4]). For P53, positive staining of more than 10% of the tumour cells was defined as positive tumour expression and staining of 10% or fewer of the cells as negative tumour expression ([@bib22]). The patients were categorised into four molecular subtypes based upon previously validated clinicopathological criteria ([@bib12]).

Follow-up
---------

The clinical and pathological records of all the patients in the study were reviewed periodically. Examinations were performed every 4--6 months for the first 5 years and every 12 months thereafter during the follow-up period. Patients were followed regularly for a minimum of 5 years of follow-up at the Harbin Medical University Cancer Hospital. The clinical records were obtained from the departments providing follow-up care. Survival was calculated in months from the date of diagnosis to the date of whichever of the following occurred first: death, last known to be alive or 20 November 2012, which was the follow-up cut-off date used in our analysis.

RNA preparation and reverse transcription
-----------------------------------------

Total RNA was extracted according to the protocol of TRIzol reagent (Invitrogen Corporation, Beijing, China) after ensuring that the tumour tissue contained more than 75% of tumour cells and had been approved by pathologists in the pathology department. RNA quality and concentration were measured by GeneQuant Pro (GE Healthcare, Buckinghamshire, United Kingdom). cDNA was synthesised from 1.0 *μ*g of total RNA in a 20 *μ*l reaction mixture using the PrimeScript RT Reagent Kit with gDNA eraser (Takara Bio Inc., Otsu, Japan).

Real-time qPCR
--------------

Real-time qPCR was performed using the ABI 7500 Fast sequence detection system (Applied Biosystems, Foster City, CA, USA) and FastStart Universal SYBR Green Master (ROX) reagent (Roche Applied Science, Mannheim, Germany) according to the manufacturers\' instructions. The primers of PGK1 were designed as follows: forward, 5′AACCAGAGGATTAAGGCTGC3′ and reverse, 5′GCCTACACAGTCCTTCAAGA3′. GAPDH was applied as the internal reference; its primers were as follows: 5′AACGACCCCTTCATTGAC3′ and reverse, 5′TCCACGACATACTCAGCAC3′. Amplification was performed under the following conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 60 s. The results of the real-time qPCR experiments were calculated using the 2^−ΔΔCt^ method. Experiments were performed in triplicate for the same reaction.

Western blotting analysis
-------------------------

Frozen tissue samples were homogenised in RIPA buffer consisting of 1% protease inhibitor mixture. The mixture was centrifuged at 12 000 g for 15 min at 4 °C and the supernatant was obtained. Total proteins were quantified. Per sample, 30 *μ*g of protein was separated onto a denaturing polyacrylamide gel containing SDS and transferred to a methanol-activated PVDF filter membrane (Bio-Rad, Hercules, CA, USA). Before immunodetection, membranes were blocked with 5% non-fat dry milk. Primary antibodies, anti-PGK1 (1:500; rabbit polyclonal; Abcam, Cambridge, MA, USA) were diluted in the buffer and incubated at 4 °C overnight. After subsequently washing with TBST, the membranes were incubated with secondary antibody (horseradish peroxidase-conjugated anti-rabbit) for 1 h at room temperature. The experiment was repeated in triplicate. The bands were detected by enhanced chemiluminescence detection reagents (Applygen Technologies Inc., Beijing, China).

Tissue microarray
-----------------

Tissue microarray (TMA) allowed the testing of a single biomarker in a high-throughput manner to test a large number of normal and cancerous tissues simultaneously. Tissue microarray (TMA) block was obtained by punching a 1.5 mm tissue cylinder (core) through a histologically representative area of each 'donor\' tumour block, which was then inserted into an empty 'recipient\' TMA paraffin block using a manual tissue arrayer as described ([@bib24]). After the construction of the array block, all of the tissue blocks were sectioned with a microtome to 4 *μ*m and affixed to the slide.

Immunohistochemical staining
----------------------------

The tissue sections were dried at 70 °C for 3 h. After deparaffinisation and hydration, the sections were washed in phosphate-buffered saline (PBS; 3 min × 3). The washed sections were treated with 3% H~2~O~2~ in the darkness for 5--20 min. After washing in distilled water, the sections were washed in PBS (5 min × 3). Antigen retrieval was performed in citrate buffer (pH 6.0) at 100 °C for 10 min. Each section was then treated with PGK1 rabbit polyclonal antibody (Abcam; at a dilution of 1:100) solution at 4 °C overnight. After washing in PBS (5 min × 3), each section was incubated with secondary antibody at room temperature for 30 min. After washing in PBS (5 min × 3), each section was treated with diaminobenzidine working solution at room temperature for 3--10 min and the slides were counterstained with haematoxylin. For negative controls, the primary antibody was substituted with PBS. The positive controls were lung cancer tissues with positive expression of PGK1 ([@bib5]).

Evaluation of PGK1 protein expression by IHC
--------------------------------------------

Semiquantitative expression levels were based on the intensity and the distribution of staining in a series of randomly selected 10 high-power fields, which were considered as representative of the average in a × 400 magnification field. Staining intensity was classified into four groups: level 0 (no staining), level 1 (weak staining=light yellow), level 2 (moderate staining=yellow brown) and level 3 (strong staining=brown). The percentage (0--100%) of the extent of reactivity was scored as follows: 0 (no positive tumour cells), 1 (fewer than 10% positive tumour cells), 2 (10--50% positive tumour cells) and 3 (more than 50% positive tumour cells). Next, the cytoplasmic expression score was obtained by multiplying the intensity and reactivity extension values. The score of 4 was used to distinguish between low and high expression of PGK1 ([@bib28]).

Statistical analyses
--------------------

All analyses were performed using statistical software (SPSS 17.0 for Windows; SPSS, Inc., Chicago, IL, USA). Associations between PGK1 expression and the patients\' clinicopathologic features, including age, tumour size, LNM, TNM stage, histologic grade, molecular subtypes and status of ER, PR, Her-2, Ki67 and P53 were assessed by the chi-square test. The Kaplan--Meier method was used to estimate OS. The influence of different variables on survival was assessed using Cox univariate and multivariate regression analyses. Risk ratios and their 95% confidence intervals were recorded for each marker. For continuous variables, Student\'s *t*-test was performed. The level of significance was set at *P*\<0.05.

Results
=======

PGK1 mRNA and protein expression in breast cancer tissues
---------------------------------------------------------

The analysis of real-time qPCR was used to confirm mRNA levels. The mean expression value of PGK1 mRNA in cancer tissues (3.542±3.737, normalised by GAPDH gene expression) was significantly higher than the value (1.995±1.711) for the corresponding normal tissues (*P*=0.010). We then defined \>1-fold changes as upregulation of PGK1 mRNA between the cancer tissues and matched normal tissues. The results revealed that 61% (28/46) of breast cancer tissues expressed a higher level of PGK1 compared with the matched normal tissues ([Figure 1A](#fig1){ref-type="fig"}).

The difference in PGK1 expression between the cancer and normal tissues reflected at the protein level was investigated using western blotting and IHC. Overall, breast cancer tissues exhibited dramatically higher levels of PGK1 protein expression compared with normal tissues. Western blotting assays demonstrated that PGK1 exhibited high expression in cancer tissues compared with the normal tissues ([Figure 1B](#fig1){ref-type="fig"}). Immunohistochemistry (IHC) analysis showed high expression of PGK1 in 136 of the cancer specimens (33.9%). However, of the 123 normal specimens, we found high PGK1 expression only in 10 (8.1%) samples (*P*\<0.001). [Figures 2A and B](#fig2){ref-type="fig"} show representative images of PGK1 staining in cancer tissue from a cancer patient and matched normal breast tissue, respectively.

Relationship between immunoreactivity of PGK1 and clinicopathologic features
----------------------------------------------------------------------------

As shown in [Table 1](#tbl1){ref-type="table"}, PGK1 expression was significantly associated with histologic grade (*P*=0.009) and the status of ER (*P*=0.004), Her-2 (*P*=0.026) and P53 (*P*=0.012). A total of 102 of 266 patients (38.3%) who were grade III had significantly higher incidences of high PGK1 expression than those patients of grade I and II (25.2%, 34 of 135, *P*=0.009). We detected high PGK1 expression in 66 of 234 (28.2%) ER-negative patients and 70 of the 167(41.9%) ER-positive patients (*P*=0.004). PGK1 was present in 29.1% (74 of 254) and 42.0% (37 of 88) of patients in the Her-2-negative group and the Her-2-positive group, respectively (*P*=0.026). High PGK1 expression was more frequently observed in P53-positive patients (*P*=0.012). However, no significant association was observed between PGK1 overexpression and age (*P*=0.430), tumour size (*P*=0.733), LNM (*P*=0.200), TNM stage (*P*=0.309), molecular subtypes (*P*=0.275) and the status of PR (*P*=0.883) and Ki67 (*P*=0.192).

Predictive significance of PGK1 expression in invasive breast cancer patients
-----------------------------------------------------------------------------

Univariate and multivariate analyses were conducted to determine the predictors for OS ([Table 2](#tbl2){ref-type="table"}). In the univariate analysis, tumour size (*P*=0.023), LNM (*P*\<0.001), TNM stage (*P*\<0.001), PGK1 expression (*P*=0.022) and the status of PR (*P*=0.005), Her-2 (*P*=0.015) and Ki67 (*P*\<0.001) were significantly associated with OS. Lymph node metastasis (*P*\<0.001, risk ratio=4.242, 95% confidence interval: 2.077--8.664) and positive Ki67 (*P*\<0.001, risk ratio=3.748, 95% confidence interval: 1.977--7.105) expression were independent factors confirmed by multivariate analysis.

[Figure 3A](#fig3){ref-type="fig"} shows that the OS was significantly higher in patients expressing elevated levels of PGK1 (*P*=0.02). The data indicated that high PGK1 expression was associated with worse OS; however, high PGK1 expression was not an independent prognostic factor.

Prognostic significance of PGK1 expression in breast cancer patients treated with paclitaxel
--------------------------------------------------------------------------------------------

Univariate and multivariate survival analyses were also used to evaluate the effects of PGK1 expression and the clinicopathologic characteristics on prognosis in patients treated with paclitaxel. Univariate analysis showed that the following factors were significantly related to OS: Ki67 (*P*=0.030) and PGK1 expression (*P*=0.001). Multivariate analysis indicated that PGK1 (*P*=0.001, risk ratio=3.127, 95% confidence interval: 1.616--6.049) was an independent predictor of OS ([Table 3](#tbl3){ref-type="table"}).

Furthermore, the Kaplan--Meier 5-year survival curves stratified for PGK1 expression in patients treated with paclitaxel are shown in [Figure 3B](#fig3){ref-type="fig"}. Among the selected patients, PGK1 expression showed significant effects on OS (*P*\<0.001).

Discussion
==========

Glycolysis plays a major role in the energy metabolism of cancer cells, which is characterised by increased glucose uptake and elevated energy generation ([@bib36]). Otto Warburg first noted in the 1920s that cancer cells undergo glycolysis even in the presence of ample oxygen ([@bib35]). This preferential use of aerobic glycolysis, termed the Warburg effect, has emerged as a metabolic hallmark of many cancers. As a result, there is great interest in understanding the markers in the glycolysis pathway.

PGK1 is an ATP-generating enzyme in the glycolytic pathway catalysing the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate ([@bib34]). In addition to the catalytic role in the glycolytic pathway, PGK1 is indeed a multifunctional molecule. PGK1 has been shown to affect DNA replication and repair in mammalian cell nuclei ([@bib33]; [@bib27]) and several studies have linked its expression to tumour biology ([@bib19]; [@bib16]; [@bib40]). Elevated levels of PGK1 protein have been detected in the serum of patients with pancreatic cancer, suggesting its potential as a biomarker for cancer ([@bib16]). The increased expression of PGK1 at the protein and mRNA levels has been associated with a poor outcome in lung adenocarcinoma patients ([@bib5]). However, several studies on the function of angiogenesis and metastasis have seemed to contradict the hypothesis that overexpression of PGK1 is a step in tumour development. PGK1 may play a role in inhibiting tumour angiogenesis by promoting an extracellular formation of angiostatin from plasmin ([@bib32]). PGK1 has been suggested to be a critical downstream target of CXCL12 and an important negative regulator of an angiogenic switch that is essential for tumour and metastatic growth ([@bib34]). Moreover, overexpression of PGK1 has been reported to reduce the expression of uPAR in human lung cancer cells H157 and to inhibit migration in H157 cells ([@bib30]).

PGK1 has been shown to be activated in breast cancer ([@bib37]; [@bib17]; [@bib6]). Overexpression of PGK1 was observed in proteins secreted in tumour interstitial fluid of breast cancer ([@bib6]). Elevated levels of PGK1 protein have been detected in breast cancer tissues compared with normal tissues ([@bib17]). PGK1 is overexpressed in Her-2-positive tissues and cell lines ([@bib37]). In this study, high expression of PGK1 in breast cancer was confirmed by both real-time qPCR (*P*=0.010) and western blotting using matched cancer-normal tissues. We also found that PGK1 was highly expressed in breast cancer tissues compared with matched normal tissues as assessed by IHC using breast cancer TMA (*P*\<0.001). Our results agreed with the data analysis from the UCSC Cancer Browser (<https://genome-cancer.ucsc.edu>, TCGA), which showed higher PGK1 expression levels in breast cancer tissues than normal breast tissues (*P*\<0.001).

To our knowledge, most of the previous studies in breast cancer either reported the findings on PGK1 expression only or just performed by cancer cells of Her-2-positive and Her-2-negative breast cancers. The significance of PGK1 expression in clinical breast cancer remains uncertain. Therefore, we analysed the correlation of PGK1 expression with the clinicopathologic features and survival in breast cancer.

Overall, positive correlations of PGK1 expression with histologic grade (*P*=0.009) and the status of ER (*P*=0.004), Her-2 (*P*=0.026) and P53 (*P*=0.012) have been demonstrated in the current study. [@bib29] compared the protein expression pattern of Her-2-positive breast cancer *vs* triple-negative breast cancer, demonstrating that PGK1 showed increased expression levels in the Her-2-positive breast cancer. It was also observed that PGK1 expression was reduced by partially switching off Her-2 signalling with Herceptin treatment ([@bib37]). These findings correspond with our results indicating that PGK1 was more highly expressed in the Her-2-positive tumours. The high expression of PGK1 in breast cancer also serves as a prognostic factor for poor OS (*P*=0.02), although it was not an independent factor. In lung cancer, PGK1 was associated with survival in the protein and mRNA study ([@bib5]). Elevated levels of PGK1 were also significantly correlated with poor outcome in 107 patients with lung adenocarcinomas using ELISA analysis and 117 adenocarcinomas and squamous lung cancers using TMA. Collectively, these data suggest that PGK1 has a significant role in the oncogenesis and progression of human breast cancer.

Chemoresistance is of paramount importance in cancer, because in the absence of an effective chemotherapy, other treatments are most often doomed to failure. Chemoresistance-associated gene discovery has shifted from the traditional empiric random screening approach to a more rational and target-based approach whereby the prognosis of patients may be predicted. Although mechanisms of chemoresistance are multiple, it has been indicated that hypoxic cells are the most chemoresistant cells ([@bib32]; [@bib3]). Additionally, the expression levels of PGK1 are controlled by oxygen tension and increased PGK1 expression may reflect more hypoxic tumours ([@bib7]). Thus, as PGK1 appears to play a key role in oncogenesis and survival of breast cancer, it may also be a prognostic target for chemotherapy ([@bib6]). PGK1 has been found to be overexpressed in cisplatin-resistant ovarian cancer ([@bib13]; [@bib20]) and in adriamycin-resistant leukemic K562 cells ([@bib25]). PGK1 may also induce a multidrug-resistant phenotype through a MDR-1-independent mechanism ([@bib9]). However, its role is ambiguous in breast cancer.

As paclitaxel is one of the most used chemotherapy drugs in breast cancer, patients whose treatment included paclitaxel were divided into two groups according to PGK1 expression for OS analysis in this study. During the follow-up period, the survival time of patients with high expression of PGK1 was shorter than that of patients with low expression of PGK1 (*P*\<0.001). Moreover, PGK1 was an independent predictor of survival in patients treated with paclitaxel (*P*=0.001). Taken together, we hypothesised that PGK1 expression might be the reason for poor prognosis in patients treated with paclitaxel. However, the exact mechanism remains unknown and requires further investigation.

Conclusion
==========

In conclusion, the identification of molecules associated with the response to chemotherapy might be important for predicting the efficacy of specific anti-neoplastic drugs and for the development of less empiric strategies regarding therapeutic choices. Our data demonstrated a significant correlation between PGK1 expression and poor prognosis in breast cancer. On the basis of the correlation between PGK1 expression and survival in breast cancer patients treated with paclitaxel, we suggested that PGK1 overexpression might be a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. Therefore, more studies are required to understand the precise role of PGK1 and to determine whether PGK1 may be used as a prognostic target.
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![**PGK1 elevated expression in fresh breast cancer tissues.** (**A**) Histogram of PGK1 mRNA expression in breast cancer.The PGK1 mRNA expression was calculated by the 2^−ΔΔCt^ method, the relative expression in each patient was presented as the ratio of T (tumour tissue)/N (normal tissue). (**B**) Representative western blotting analysis of PGK1 expression in breast tissues. The levels of GAPDH were used as an internal control.](bjc2015114f1){#fig1}

![**Immunohistochemical staining of PGK1 in breast tissues ( × 400).** (**A**) PGK1 low-expression specimen (normal breast tissue). (**B**) PGK1 high-expression specimen (breast cancer tissue).](bjc2015114f2){#fig2}

![**Kaplan--Meier analysis for survival based on PGK1 expression.** (**A**) Survival curves showing the correlation of PGK1 with OS in breast cancer patients (*P*=0.02). (**B**) Overall survival based on PGK1 expression in patients treated with paclitaxel (*P*\<0.001).](bjc2015114f3){#fig3}

###### Correlation between PGK1 expression and clinicopathological features

  **Characteristics**     **Cases**   **Negative**   **Positive**  ***P*** **value**
  ---------------------- ----------- -------------- -------------- -------------------
  **Age**                                                          
  \<50                       219       141 (64.4)     78 (35.6)    0.430
  ⩾50                        182       124 (68.1)     58 (31.9)     
  **Tumour size**                                                  
  ⩽2                         137       89 (65.0)      48 (35.0)    0.733
  \>2                        264       176 (66.7)     88 (33.3)     
  **LNM**                                                          
  Negative                   177       123 (69.5)     54 (30.5)    0.200
  Positive                   224       142 (63.4)     82 (36.6)     
  **TNM stage**                                                    
  I, II                      267       181 (67.8)     86 (32.2)    0.309
  III                        134       84 (62.7)      50 (37.3)     
  **Histologic grade**                                             
  I, II                      135       101 (74.8)     34 (25.2)    0.009
  III                        266       164 (61.7)     102 (38.3)    
  **ER status**                                                    
  Negative                   234       168 (71.8)     66 (28.2)    0.004
  Positive                   167       97 (58.1)      70 (41.9)     
  **PR status**                                                    
  Negative                   176       117 (66.5)     69 (33.5)    0.883
  Positive                   225       148 (65.8)     77 (34.2)     
  **Her-2 status**                                                 
  Negative                   254       180 (70.9)     74 (29.1)    0.026
  Positive                   88        51 (58.0)      37 (42.0)     
  **Ki67 status**                                                  
  \<14%                      204       141 (69.1)     63 (30.9)    0.192
  ⩾14%                       197       124 (62.9)     73 (37.1)     
  **P53 status**                                                   
  Negative                   78        61 (78.2)      17 (21.8)    0.012
  Positive                   323       204 (64.2)     119 (36.8)    
  **Subtype**                                                      
  Luminal A                  78        54 (69.2)      24 (30.8)    0.275
  Luminal B                  129       84 (65.1)      45 (34.9)     
  Her-2 overexpression       52        31 (59.6)      21 (40.4)     
  Basal-like                 83        62 (74.7)      21 (25.3)     

Abbreviations: ER=oestrogen receptor; LNM=lymph node metastasis; PR=progesterone receptor; TNM=tumour node metastasis.

###### Prognostic factors in the Cox proportional hazards model

  **Variables**          **Risk ratio**   **Univariate 95% CI**   ***P***   **Risk ratio**   **Multivariate 95% CI**   ***P***
  ---------------------- ---------------- ----------------------- --------- ---------------- ------------------------- ---------
  **Age(years)**                                                                                                       
  ⩾50/\<50               1.012            (0.612--1.675)          0.962                                                 
  **Tumour size (cm)**                                                                                                 
  ⩽2.0/\>2.0             2.036.           (1.103--3.759)          0.023                                                 
  **LNM**                                                                                                              
  Positive/negative      4.565            (2.317--8.995)          0.001     4.242            (2.077--8.664)            \<0.001
  **TNM stage**                                                                                                        
  I and II/ III          3.443            (2.059--5.757)          \<0.001                                               
  **Histologic grade**                                                                                                 
  I and II/ III          1.325            (0.757--2.319)          0.325                                                 
  **ER status**                                                                                                        
  Positive/negative      0.879            (0.524--1.475)          0.626                                                 
  **PR status**                                                                                                        
  Positive/negative      0.481            (0.287--0.803)          0.005                                                 
  **Her-2 status**                                                                                                     
  Positive/negative      1.958            (1.140--3.365)          0.015                                                 
  **Ki67 status**                                                                                                      
  Positive/negative      3.355            (1.896--5.938)          \<0.001   3.748            (1.977--7.105)            \<0.001
  **P53 status**                                                                                                       
  Positive/negative      0.929            (0.503--1.715)          0.815                                                 
  **PGK1 expression**                                                                                                  
  Positive/negative      1.802            (1.089--2.983)          0.022                                                 

Abbreviations: CI=confidence interval; ER=oestrogen receptor; LNM=lymph node metastasis; PR=progesterone receptor; TNM=tumour node metastasis.

###### Prognostic factors in the Cox proportional hazards model of patient who are treated with paclitaxel

  **Variables**          **Risk ratio**   **Univariate 95% CI**   ***P***   **Risk ratio**   **Multivariate 95% CI**   ***P***
  ---------------------- ---------------- ----------------------- --------- ---------------- ------------------------- ---------
  **Age(years)**                                                                                                       
  ⩾50/\<50               1.269            (0.669--2.405)          0.466                                                 
  **Tumour size (cm)**                                                                                                 
  ⩽2.0/\>2.0             1.848            (0.847--4.034)          0.123                                                 
  **LNM**                                                                                                              
  Positive/negative      1.727            (0.674--4.425)          0.255                                                 
  **TNM stage**                                                                                                        
  I and II/ III          1.281            (0.669--2.456)          0.455                                                 
  **Histologic grade**                                                                                                 
  I and II/ III          1.145            (0.542--2.419)          0.722                                                 
  **ER status**                                                                                                        
  Positive/negative      1.153            (0.608--2.186)          0.663                                                 
  **PR status**                                                                                                        
  Positive/negative      0.686            (0.362--1.301)          0.249                                                 
  **Her-2 status**                                                                                                     
  Positive/negative      1.291            (0.650--2.564)          0.466                                                 
  **Ki67 status**                                                                                                      
  Positive/negative      2.227            (1.081--4.587)          0.030                                                 
  **P53 status**                                                                                                       
  Positive/negative      2.682            (0.951--7.560)          0.062                                                 
  **PGK1 expression**                                                                                                  
  Positive/negative      3.127            (1.616--6.049)          0.001     3.127            (1.616--6.049)            0.001

Abbreviations: CI=confidence interval; ER=oestrogen receptor; LNM=lymph node metastasis; PR=progesterone receptor; TNM=tumour node metastasis.
